Profile data is unavailable for this security.
About the company
Calliditas Therapeutics AB, formerly Pharmalink AB, is a Sweden-based specialty pharmaceutical company. It is focused on the development and commercialization of its product candidate Nefecon, a treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Nefecon is derived from the TARGIT technology, in which the capsule containing the active drug substance is coated in a way that the capsule remains intact as it passes through the stomach and intestine until it reaches the lower small intestine, where the release of content takes place. Nefeco combines time lag effect with a concentrated release of the active substance budesonide, within a designated target area.
- Revenue in SEK (TTM)1.21bn
- Net income in SEK-466.18m
- Incorporated2004
- Employees181.00
- LocationCalliditas Therapeutics ABD5, Kungsbron 1,STOCKHOLM 111 22SwedenSWE
- Phone+46 84113005
- Fax+46 86113303
- Websitehttps://www.calliditas.se/
